CO2016001839A1 - Composiciones de compuestos selenoórganicos y métodos de uso de los mismos - Google Patents

Composiciones de compuestos selenoórganicos y métodos de uso de los mismos

Info

Publication number
CO2016001839A1
CO2016001839A1 CONC2016/0001839A CO2016001839A CO2016001839A1 CO 2016001839 A1 CO2016001839 A1 CO 2016001839A1 CO 2016001839 A CO2016001839 A CO 2016001839A CO 2016001839 A1 CO2016001839 A1 CO 2016001839A1
Authority
CO
Colombia
Prior art keywords
compositions
methods
formula
selenoorganic compounds
compounds
Prior art date
Application number
CONC2016/0001839A
Other languages
English (en)
Inventor
Ronan Power
Zi-Jian Lan
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/855,128 external-priority patent/US9642874B2/en
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of CO2016001839A1 publication Critical patent/CO2016001839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se relaciona con composiciones que comprenden compuestos de selenio, tales como 5’-Metilselenoadenosina, Se-Adenosil-L-homocisteína, Gama-glutamil-metilseleno-cisteína, un compuesto de la Fórmula (I), Fórmula (II), o Fórmula (III), y combinaciones de los mismos, y métodos para utilizar los mismos para modular el metabolismo de glucosa en un sujeto.
CONC2016/0001839A 2015-09-15 2016-09-13 Composiciones de compuestos selenoórganicos y métodos de uso de los mismos CO2016001839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/855,128 US9642874B2 (en) 2014-03-14 2015-09-15 Compositions of selenoorganic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2016001839A1 true CO2016001839A1 (es) 2018-03-20

Family

ID=56920509

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2016/0001839A CO2016001839A1 (es) 2015-09-15 2016-09-13 Composiciones de compuestos selenoórganicos y métodos de uso de los mismos

Country Status (7)

Country Link
EP (1) EP3144001B1 (es)
CA (1) CA2939592A1 (es)
CL (1) CL2016002283A1 (es)
CO (1) CO2016001839A1 (es)
IL (1) IL247645A0 (es)
PE (1) PE20170500A1 (es)
WO (1) WO2017048252A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014954B2 (en) * 2017-05-19 2021-05-25 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
KR20020073342A (ko) 1999-12-03 2002-09-23 더 리젠트 오브 더 유니버시티 오브 캘리포니아, 샌디에고 포스포네이트 화합물
US6903081B2 (en) 2000-03-31 2005-06-07 Purdue Research Foundation Phosphoramidates and methods therefor
WO2003091264A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
JP4332496B2 (ja) 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
US8865763B2 (en) * 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
JP4753683B2 (ja) * 2005-10-14 2011-08-24 オルテック インコーポレイテッド 細胞機能を変化させるための方法および組成物
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
US8796241B2 (en) * 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
WO2013151975A1 (en) * 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
CN114533753A (zh) * 2013-03-15 2022-05-27 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
JP6313479B2 (ja) * 2014-03-14 2018-04-18 オールテック，インク． 有機セレン化合物の組成物およびその使用方法

Also Published As

Publication number Publication date
WO2017048252A1 (en) 2017-03-23
PE20170500A1 (es) 2017-05-11
EP3144001B1 (en) 2021-08-11
EP3144001A1 (en) 2017-03-22
CA2939592A1 (en) 2017-03-15
IL247645A0 (en) 2017-01-31
CL2016002283A1 (es) 2017-03-17

Similar Documents

Publication Publication Date Title
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
DOP2017000298A (es) Reguladores de nrf2
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20160272A (es) REGULADORES DE Nrf2
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2019001664A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP14013196A (es) Compuestos sustituidos fungicidas de 2-[2-halogenalquil-4-(fenoxi)-fenil]-1-[1,2,4]triazol-1-il-etanol
SV2018005656A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina,un proceso para su preparacion y composiciones farmaceuticas que los contiene
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
NI201500140A (es) Compuestos y composiciones terapéuticos
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
CO6741218A2 (es) Composición pesticida y procesos relacionados con el mismo
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
MX2018015938A (es) Metodos para inhibir la conversion de colina en trimetilamina (tma).
BR112018006314A2 (pt) composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos